Phase II Study of Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
Latest Information Update: 11 Dec 2023
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Lorlatinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 29 Nov 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 20 Sep 2023 Status changed from not yet recruiting to recruiting.
- 06 Sep 2023 Planned initiation date changed from 1 Aug 2023 to 1 Sep 2023.